GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Additional Paid-In Capital

CSL (CSLLY) Additional Paid-In Capital : $0 Mil(As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is CSL Additional Paid-In Capital?


CSL Additional Paid-In Capital Historical Data

The historical data trend for CSL's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Additional Paid-In Capital Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CSL Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

CSL Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CSL's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Additional Paid-In Capital
Comparable Companies
ASX:TLX ASX:NEU ASX:MSB ASX:CU6 ASX:CUV ASX:IMU ASX:IMM ASX:OPT ASX:PYC ASX:BOT OCSE:NOVO B VRTX REGN MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX OCSE:GMAB
Traded in Other Exchanges
CMXHF:USA CSJ:Germany CSL:Australia
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
Website
https://www.csl.com
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.